spacer
The Healthcare Sales & Marketing Network celebrates 22 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  NeuVax 

 HSMN NewsFeed - 29 Jul 2015
Galena Biopharma Launches Zuplenz(R) (ondansetron) Oral Soluble Film
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 21 Aug 2014
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 May 2013
William L. Ashton Joins Galena Biopharma's Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Dec 2012
Galena Biopharma Announces Signature of Commercialization Partnership With Teva for Israel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 May 2012
Galena Biopharma Announces Expansion of Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2012
Galena Biopharma Initiates Patient Enrollment in NeuVax(TM) Phase 3 PRESENT Trial to Prevent Breast Cancer Recurrence
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2011
Galena Biopharma Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2011
Apthera and RXi Pharmaceuticals Announce Definitive Merger Agreement
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 31 Mar 2011
RXi Pharmaceuticals Aggressively Moves into Late-Stage Clinical Development with the Agreement to Acquire Apthera, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 8 Jan 2010
Dr. Mark W. Schwartz Joins Apthera as President & CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Jun 2009
Apthera Announces Product License Agreement With Kwang Dong Pharmaceutical Co., Ltd.
Biopharmaceuticals Oncology Licenisng
 HSMN NewsFeed - 14 Apr 2008
Low HER2 Expressing Breast Cancer Patients Respond Preferentially to Apthera's NeuVax(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2008
Apthera Files a Phase III Special Protocol Assessment with FDA for NeuVax(TM) in Early-Stage Breast Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
HER2/neu Vaccine Results Spurs Phase III Planning by Apthera, Inc.
Biopharmaceuticals Oncology
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.